Developing RNA Screening for Cancer Diagnosis

At another stop on the Road to 50 States trip, Marc Wolff, CEO of Calviri, talks to Pharma's Almanac about the advanced technology Calviri is currently using to screen RNA to help identify cancer cells as early as possible.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer by combining a unique, highly immunogenic source of neoantigens with a peptide array platform. On our course to eradicate cancer we will develop new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting.

  • Clinical trials are in progress to demonstrate the feasibility of providing prophylactic vaccines that prevent cancer.
  • Partnerships are formed to collaboratively established the viability of early cancer diagnosis.
  • FAST vaccine trials are being initiated that could dramatically reduce the time and expense of cancer treatments.